 |
 |
|
|
|
| LevodopaCAS No. 59-92-7 |
 |
| Levodopa |
 |
Levodopa
Formula C9H11NO4
Molecular weight of 197.19
CAS No. 59-92-7
EINECS Registry No. 200-445-2
Melting point 295¡Æ C
Than the optical rotation -11.7 o The (C = 5.3, 1N HCl)
Hazard Symbols Xn (harmful)
Risk Codes R22 (Harmful if swallowed)
Safety instructions S24/25 (avoid contact with skin, eyes)
Use: to antiparkinsonian drugs. Through the blood-brain barrier into the brain tissue into dopamine by dopa decarboxylase decarboxylation to play a role.
For essential tremor paralysis and non-drug immunogenicity paralysis agitans syndrome, pair, mildly better, less severe or elderly.
|
 |
Levodopa
Formula C9H11NO4
Molecular weight of 197.19
CAS No. 59-92-7
EINECS Registry No. 200-445-2
Melting point 295¡Æ C
Than the optical rotation -11.7 o The (C = 5.3, 1N HCl)
Hazard Symbols Xn (harmful)
Risk Codes R22 (Harmful if swallowed)
Safety instructions S24/25 (avoid contact with skin, eyes)
Use: to antiparkinsonian drugs. Through the blood-brain barrier into the brain tissue into dopamine by dopa decarboxylase decarboxylation to play a role.
For essential tremor paralysis and non-drug immunogenicity paralysis agitans syndrome, pair, mildly better, less severe or elderly.
|
| Industrial field |
pharmaceutical |
|
|
 |
|
|
|
|
|
 |
| There are no existing companies to distribute selected chemical product |
|
 |
|
|
|
